Archemin takes a broad approach to service continuity, including potential effects of an outbreak such as COVID-19. While there is currently no foreseen impact to Archemin’s operations, we wanted to provide some detail regarding our preparedness should the situation change.
Archemin have plans in place for enabling remote work in a situation like this. Possible impact to systems – First and foremost there are no anticipated impacts to Archemin’s systems and services.
- One of the benefits of the Archemin business model is the ability to reallocate collaborators between business units, and redistribution of workload which we continue to monitor closely.
- A general principle of cloud service operations is remote management and administration. We see no effect to our ability to manage the systems used to support our services, and have confirmed adequate capacity for staff to work remotely at scale.
Archemin's services are designed for remote administration. However, with the recently increases in incidence of COVID-19 we wanted to provide specific details around support of the service should Archemin collaborators be constrained to work from home.
- Every collaborator has the ability to securely provide services without direct access to the corporate location.
- As provider of pharmaceutical consultancy services we have the capability of ensuring continued operations with multiple subject matter experts in a wide range of disciplines.
- Employees all have access to needed resources to take action from home or the office.
- The possible redistribution of workload allows for sustained support should issues arise and ensures that resources are available should individuals fall ill.
While Archemin puts the safety and well-being of its employees at the forefront, our approach is expected to allow for uninterrupted service operation should the virus spread significantly.